Diversis Capital acquires Caligor Rx

Caligor sources and distributes comparator drugs for clinical trials worldwide from the US and UK

Tammy Bishop, MD of Caligor Rx, has been named Caligor's CEO following the acquisition of the company by Diversis Capital. (Photo: Business Wire)

Diversis Capital, a North American private equity firm, has purchased the majority of the assets of Caligor Rx.

Based in Secaucus, New Jersey with an additional facility in Dartford, UK, Caligor provides logistics and supply chain services.

Financial terms of the deal have not been disclosed.

From its roots as a pharmacy started in 1919, Caligor has established itself as a leader in sourcing and distributing comparator drugs for clinical trials worldwide. Complementing its comparator business, the firm provides regulatory expertise and strategic services for setting up Global Access Programmes (GAP). These supply investigational medicines to individual patients, and groups of patients, who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives. Caligor has implemented and managed these programmes in more than 70 countries.

Kevin Ma, an MD at Diversis Capital, which is based in Los Angeles, said Caligor has a strong, successful track record of delivering clinical trial supply and logistics services to the pharmaceutical and biotechnology industries.

'We are excited about driving the next stage of Caligor’s growth and shaping its long-term strategy,' he said.

'We will provide additional resources and operational expertise to expand the company’s comparator and GAP offerings, broaden the reach of its businesses to new geographic regions, enhance its logistics capabilities and build on its leadership position.'

Diversis plans to invest in Caligor to enhance its sales and marketing, logistics capabilities, distribution infrastructure and service offerings.

These investments will include a new warehouse in Dartford, which is scheduled to open towards the end of this year, and provide about five times more space than the current UK facility.

Tammy Bishop, previously Caligor's MD, becomes CEO of the company.

'Our entire global team is delighted to become part of the Diversis portfolio,' she said. 'This acquisition underscores a strong belief in Caligor’s long-term growth. Diversis’ commitment to invest significant resources in Caligor – in our people, systems and capabilities – ultimately benefits clients as well as employees.'